Imagine that in a world where thousands of new studies are published every year, and hundreds of studies are conducted on any one condition, that one gleaming, gold-standard study has the ability to completely determine the course of treatment for one condition. For decades.
If you find that hypothetical situation difficult to swallow, you’re not alone. Experts and specialists of a condition such as attention deficit hyperactivity disorder (ADHD) rarely rely on a single study’s results to help guide their treatment decisions. And even when they do, it’s nearly always done within the context of a specific patient’s individualized needs.
So can a single study have such influence over the choice of treatments in ADHD? Let’s find out.
The claimed magical research is the NIMH’s Multimodal Treatment of Attention Deficit Hyperactivity Disorder study published in 1999 (MTA Cooperative Group, 1999). Alan Schwarz, writing for The New York Times, says:
But in retrospect, even some authors of the study — widely considered the most influential study ever on A.D.H.D. — worry that the results oversold the benefits of drugs, discouraging important home- and school-focused therapy and ultimately distorting the debate over the most effective (and cost-effective) treatments.
Considered by whom? Schwarz never says. Clearly it is an important milestone in the understanding of the treatment of ADHD. But all of science is every-changing, and neither researchers nor clinicians look at a study published 14 years ago and says, “Well, we answered that question, let’s close up shop and call it a day.”
So what exactly is the problem with this rigorous, NIMH-funded ((No pharmaceutical funding was involved in the study.)) research?
The study was structured to emphasize the reduction of impulsivity and inattention symptoms, for which medication is designed to deliver quick results, several of the researchers said in recent interviews.
Less emphasis was placed on improving children’s longer-term academic and social skills, which behavioral therapy addresses by teaching children, parents and teachers to create less distracting and more organized learning environments. ((Schwarz, I believe, also doesn’t do the study’s major findings justice, simplifying what the research authors actually said in the paper. They acknowledged, for instance, the importance of considering combined treatment when called for to help deal with non-ADHD domain problems: “combined treatment also fared significantly better than community care for all 5 non-ADHD domains: parent-reported oppositional/aggressive symptoms, parent-reported internalizing problems, teacher-reported social skills, parent-child relations, and reading achievement.”))
The last time I looked, symptoms of impulsivity and inattention are at the core of the definition of ADHD. So it’s not really surprising that the study focused on these symptoms.
Poor social skills, on the other hand, are seen more as a direct result of these kinds of symptoms — an inability to engage in sustained attention to an activity — rather than as a stand-alone problem. People with ADHD have trouble with academic functioning and social skills because of inattention and impulsivity issues. ((Looking at it from the flip side, people with ADHD generally do not have inattention or impulsivity problems because of poor social skills or an inability to cognitively comprehend the educational material they are expected to learn. ))
Nobody would argue that helping children deal with these related issues is vitally important as well. And the evidence is clear — behavioral treatments have been demonstrated to be helpful for children with co-occurring disorders and these kind of related symptoms. But they have been shown to be far less effective in the treatment of the core symptoms of ADHD.
Can One Study Blot Out All Other ADHD Research?
But even if we want to second-guess the design of a 14-year-old study and suggest the researchers should’ve used their crystal ball to not focus so much on the core symptoms of how we commonly define ADHD, you also have to buy into the belief that this single study is all that anyone has read in the ADHD literature. For the past 14 years. ((In fact, not mentioned by Schwarz is that the original 1999 MTA study spawned over a dozen, equally-important followup studies!))
Last time I checked, most experts, clinicians and researchers who study ADHD don’t work that way. Instead, they keep up on the research literature, reading the major studies that come out every single month on attention deficit disorder.
Since the 1999 NIMH study was published, PsycINFO shows that over 2,000 additional peer-reviewed studies have been published on the topic of ADHD treatment. Dozens have been published on the efficacy of behavioral treatments. Not all of them have been positive.
For instance, in a large systematic review and meta analyses of randomized controlled trials of dietary and psychological treatments for ADHD published earlier this year (Sonuga-Barke et al., 2013), the researchers initially found that all dietary and psychological treatments produced statistically significant effects when using raters closest to the therapeutic setting.
However, things changed when blinded assessment was employed: the significant effects disappeared for all but free fatty acid supplementation and artificial food color exclusion (for those with a food sensitivity). In other words, behavioral therapy and cognitive training didn’t meet the cut for being shown as effective treatments for ADHD, leading these researchers to conclude:
Better evidence for efficacy from blinded assessments is required for behavioral interventions, neurofeedback, cognitive training, and restricted elimination diets before they can be supported as treatments for core ADHD symptoms.
Another recent meta-analysis from Rapport et al. (2013) comes to similar conclusions when looking at cognitive training programs designed to help kids with ADHD. The only positive effect they could find was for short-term memory improvement in such programs. Everything else was non-significant:
[…] training attention did not significantly improve attention and training mixed executive functions did not significantly improve the targeted executive functions (both nonsignificant: 95% confidence intervals include 0.0). Far transfer effects of cognitive training on academic functioning, blinded ratings of behavior (both nonsignificant), and cognitive tests (d= 0.14) were nonsignificant or negligible.
Worse, they found the same rater bias effects as the above meta analytic review found:
Unblinded raters (d= 0.48) reported significantly larger benefits relative to blinded raters and objective tests.
In plain language, this means that researchers sometimes introduce bias into their results by using raters to help judge the effectiveness of the treatment intervention. Such raters can be unintentionally (and unconsciously) biased, producing results that, upon further analysis, aren’t as strong as the original research suggested.
Our Take on the Best Treatment for ADHD
There is nothing wrong with calling attention to the emphasis of medication treatment over other types of treatment. Indeed, there is too much quickness — mostly by well-meaning pediatricians and family doctors — in reaching for the prescription pad to treat ADHD. And a reluctance and difficulty in seeking out additional, or alternative, treatments for ADHD, like psychosocial or behavior therapy.
But there is something wrong with a hyperbolic claim that a single study published 14 years ago somehow caused or significantly contributed to this problem. Or that the researchers who were interested in studying the core symptoms of ADHD somehow missed the mark by not significantly expanding the scope (and therefore, the cost) of their study by looking at things that were related to, but were not the core symptoms, of ADHD.
The NIMH study is a solid study that helped increase our understanding of the treatments for ADHD. But it was not the end of the story. One of the followup studies (Molina et al., 2009) to the original MTA study found an important nugget of prognosis for ADHD:
[…. E]arly ADHD symptom trajectory regardless of treatment type is prognostic. This finding implies that children with behavioral and socio demographic advantage, with the best response to any treatment, will have the best long-term prognosis.
In other words, if you’re not poor and have ready access to good treatment and schools, whatever treatment your child responds to best is going to be the best treatment for them. Try different ones until you find one that works best for them.
Our understanding of conditions like attention deficit disorder is expanding and increasing all the time. Science nor knowledge ends with a single study, and it’s a bit silly to suggest it does.
Read the NY Times article: A.D.H.D. Experts Re-evaluate Study’s Zeal for Drugs
References
Molina, BSG et al. (2009). The MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Academy of Child & Adolescent Psychiatry, 48, 484-500.
The MTA Cooperative Group. (1999). A 14-Month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder (ADHD). Arch Gen Psychiatry, 56, 1073-1086.
Rapport, MD et al. (2013). Do programs designed to train working memory, other executive functions, and attention benefit children with ADHD? A meta-analytic review of cognitive, academic, and behavioral outcomes Clinical Psychology Review, 33, 1237-1252
Sonuga-Barke, EJS et al. (2013). Nonpharmalogical interventions for ADHD: Systematic review and meta analyses of randomized controlled trials of dietary and psychological treatments. The American Journal of Psychiatry, 170, 275-289.
3 comments
I posted about Adult ADD just before coming here, and I advise readers to seek out the source of that post, the Jan/Feb 2014 issue of Scientific American Mind, the article entitled “ADHD Grows Up” by Bilkey, Surman, and Weintraub. I’d offer the link but the publication only gives you a preview, well, here it is anyway:
http://www.scientificamerican.com/article.cfm?id=adults-can-have-adhd-too
I did a cut and paste of the meat of the article, how to utilize skills and not just depend on pills.
Just remember this, from a provider who has watched the drug seeking of stimulants literally explode in number the past 4 or so years, at least in the areas I have worked in around Washington DC: stimulants are NOT benign medications, and certainly have ceiling dosage limits. But, you can always find someone to give you what you want.
However, is it really what you need?…
Nice post by the way Dr G!
Many people cannot afford therapy, or can’t take off work to go to or to take a child to therapy. Medication copays are often just $10 a month and the medications can be prescribed by a family doctor.
I suppose these factors are just as important to consider when making treatment recommendations.
Dear Dr. Grohol and All: Kudos to Dr. Grohol for an excellent scientific analysis of the NYTimes article written by Alan Schwarz. And, kudos, for keeping it scientific.
There are many rational and scientific weaknesses in Mr. Schwarz’s series of articles on ADD dating back to mid-2012 and a pattern of biased analysis and logic that cannot be ignored. Clearly, after making his mark by being the foremost journalist to inform the public about the truth of sports-related concussions through New York Times articles, he has decided to push an agenda at the New York Times that is so transparently biased for the purpose of scaring readers about “stimulants” that it would be scientifically laughable if it wasn’t so serious.
Dr. Grohol is way too kind to Mr. Schwarz, not only in this post but in Dr. Grohol’s earlier posts about the “overdiagnosis” of ADD.
I have sent my book to Mr. Schwarz and talked with him briefly on the phone, and it is clear that he does not want to know the truth about traditional ADD medications that consist of mostly controlled substances classified as Schedule 2 drugs by laws passed in and around 1971. This kind of fear-mongering sponsored by one of the traditional giants in journalism, the New York Times, is unforgiveable.
A few bullet points because there is no way I can discuss the nuances here. 1. Since 2008, the literature is clear about both the downside and the upside of the ADD brain. 2. Both the downside and the upside are produced by the same common-denominator, dopamine dysfunctions. 3. The dopamine system of bridges (neurotransmitters) is very complex with ten significant genes controlling all aspects of the dopamine bridge system. 4. The downside of the ADD brain is poor working memory (working memory is almost entirely dopamine function dependent). 5. The upside is more difficult to understand because many terms have missed the target in describing it so far — terms like risk taking, thrill seeking, adventurous, etc. The two terms I use are emergency capability and threat tolerance. 6. Threat treats ADD — it percolates dopamine in the emotional brain (which I call the Threat Monitor Center) and the dopamine spilling out due to threat optimizes poor working memory.
Thus, the ADDer gets “better” in threat, conflict, competitive, defensive, and disgusting environments. Better means increased working memory (calmer, better judgment, “in the zone”) and faster reaction times. The non-ADDer baseline dopamine optimal brain is decidedly problematic in the same threat environments, with dopamine presence exceeding optimum and creating poor cognitive function (confusion and inefficient data processing due to data “detours”), “overamping,” and longer reaction times. In other words, too many dopamine bridges (above optimal) is just as bad as too few dopamine bridges.
So, what’s my point? My point is this. The medications available are literally targeting different aspects of the dopamine system. We do not yet know exactly what they are doing in the intact human brain, but we know they are not the same and CANNOT be compared head-to-head, unless you genotype subjects and figure out what kind of ADD they have from their genotype.
Different problematic genotypes exist but poor working memory and behavior is typically similar no matter what problematic genotype is present. This means that the best method for finding the correct medication is to aggressively do trial doses of the different medications that are available looking for the one that has no significant side effects, and is either neutral on sleep or fixes sleep problems. (90% of ADDers have significant sleep problems and sleep quality.)
Adderal is particularly problematic for many reasons and many more bona fide ADDers are taking it than should be taking it. It is a longer story, but in essence, the problem lies in the fact that it contains two different amphetamines which have very different properties and likely target different aspects of the dopamine system. In other words, one of them might be right, and the other completely wrong. Unless you know that, you don’t know what to look for and what to do about it.
Significant side effects are always due to the wrong medication or too much of the right medication and are 90% of the time the same side effects that above optimal dopamine produces — upset stomach, nausea, increased anxiety, over-amping, more irritable rather than less, jitteriness, muscle tension of many kinds, increased heart rate, increased blood pressure, a buzz, worse sleep, a crash. In other words, those Vyvanse commercials on television that are 3/4 about side effects, should end by saying, “if you get these side effects talk to your doctor, there may be a better medication for you.” As if pharmaceutical companies would say that, right? But, that is the truth.
So, in that regard there have been no significant studies of medications that have investigated subjects taking the same medications and dividing them into at least two groups, those experiencing significant side effects and “adapting” to them, and those experiencing no significant side effects, including neutral or positive on sleep.
The New York Times does an injustice by not telling its readers why Adderall is particularly problematic and by using worst case scenarios to fearmonger about all ADD medications. The single study Dr. Grohol refers to in this post is fatally flawed from the outset since it makes no attempt to separate out the two general groups of medication users, those with significant side effects, and those without. It is garbage in, garbage out, and literally none of the head-to-head medication response (efficacy) studies I know of have any scientific credibility.
Most medication studies have concluded that medications are a wash, with no significant upside or downside. Well, yah, when you group side-effectors with non-side-effectors in a single study, guess what? A wash.